Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi… changes any severe adverse events (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (very low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · newly‐diagnosed EOC
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with… leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (high certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · people with a primary brain tumour
1 finding from 1 review
Intervention not reported
Intervention: high‐dose radiotherapy Comparison: low‐dose radiotherapy Outcome: neurocognitive impairment at 2 years after treatment · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: high‐dose radiotherapy Comparison: low‐dose… (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention: high‐dose radiotherapy Comparison: low‐dose radiotherapy Outcome: neurocognitive impairment at 5 years after treatment · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: high‐dose radiotherapy Comparison: low‐dose… (very low certainty).
1 finding from 1 review
High‐grade cervical, vulval, vaginal, penile, or anal intraepithelial neoplasia · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
High‐grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and cervical cancer · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine showed no clear difference in high‐grade cervical intraepithelial neoplasia, adenocarcinoma in… compared with quadrivalent HPV vaccine (high certainty).
1 finding from 1 review
High‐grade cervical, vulval, and vaginal disease · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine showed no clear difference in high‐grade cervical, vulval, and vaginal disease at up to 4.5‐year compared with quadrivalent HPV vaccine (high certainty).
1 finding from 1 review
High‐grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and cervical cancer · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
High‐grade cervical, vulval, and vaginal disease · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival: higher‐dose WBRT vs control (3000 cGy/10 daily fractions)No. of participants: 846(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in overall survival: higher‐dose WBRT vs control (3000 cGy/10 daily… compared with WBRT control (moderate certainty).
1 finding from 1 review
HR 0.97 [0.83, 1.12]
Studies not reported
Moderate
Neurological function improvement: higher‐dose WBRT vs control dose WBRT (3000 cGy/10 fractions)No. of participants: 1480(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in neurological function improvement: higher‐dose WBRT vs control dose… compared with WBRT control: neurological function improvement (moderate certainty).
1 finding from 1 review
OR 1.14 [0.92, 1.42]
Studies not reported
Moderate
Intervention not reported
Progression of CIN to a higher grade of CIN · women with CIN 2 or CIN 3
It is very uncertain whether the intervention changes progression of CIN to a higher grade of CIN (very low certainty).
1 finding from 1 review
RR 0.54 [0.06, 5.24]
25 participants
Very low
Diarrhoea (grade 2+) · participants with cancer treated with chemotherapy
Probiotics showed no clear difference in diarrhoea grade 2 or higher compared with placebo (low certainty).
1 finding from 1 review
Grade 3 to 4 diarrhoea · participants with cancer treated with chemotherapy
Probiotics showed no clear difference in diarrhoea grade 3 or higher compared with placebo (low certainty).
1 finding from 1 review
Grade ≥ 3 diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy)
Probiotics may leads to lower severity of diarrhoea: grade 3 or higher compared with other active treatment (low certainty).
1 finding from 1 review
Diarrhoea (grade 2+) · participants with cancer treated with radiotherapy (with or without chemotherapy)
Probiotics showed no clear difference in diarrhoea grade 2 or higher compared with placebo (low certainty).
1 finding from 1 review
Grade 3 to 4 diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy)
1 finding from 1 review
Mean GI symptom scores (IBDQ‐B) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
1 finding from 1 review